StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Keros Therapeutics's EV/EBITDA was 0.8× on Jan 30, 2026.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Jan 30, 20260.8×−2.3
2025Dec 31, 20253.1×–

More Keros Therapeutics figures

See a number that looks wrong?